Pharmalink announces positive results in Phase 2b trial of Nefecon
Pharmalink AB announced that the NEFIGAN Trial of Nefecon® for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.
The NEFIGAN Trial is a Phase 2b randomized double-blinded, placebo-controlled clinical trial assessing the safety and efficacy of two different doses of Nefecon – a new oral modified-release capsule of the corticosteroid, budesonide – administered daily over a nine-month treatment period to primary IgA nephropathy patients with persistent proteinuria despite optimized standard-of-care therapy. The trial has been conducted in 62 centers in 10 European countries and was originally intended to recruit 90 patients. Over-recruitment has increased this to more than 150 patients.
“Meeting the primary endpoint of the NEFIGAN Trial with such high significance and at this interim analysis is a tremendous result and major milestone for Pharmalink,” said Johan Häggblad, Ph.D., Managing Director of Pharmalink. “The NEFIGAN Trial was conducted with excellent efficiency, and the fact that the patient recruitment target was also exceeded so rapidly indicates the clear unmet medical need for new treatments for IgA nephropathy patients. We would like to thank all the investigators and patients who contributed to this clinical trial and look forward to the further development of Nefecon.”
The interim analysis, conducted by the Data & Safety Monitoring Board (DSMB), demonstrated that Nefecon treatment (both treatment groups combined) resulted in a highly significant improvement [p=0.0066 on an intention-to-treat (ITT) basis] in the primary endpoint, defined as the mean reduction in urine protein creatinine ratio (UPCR) during the nine-month treatment period, as compared to placebo. The result will enable an optimal dose of Nefecon to be selected for a Phase 3 registration trial.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
